Impacting global economies severely
”NEUROPATHIC PAIN has a severe impact not only on individual sufferers’ physical and mental health but also on national economies . In the US, almost 20% of adults suffer from chronic pain (2016) with an estimated annual cost of 560 bUSD in direct medical costs, lost productivity, and disability programs.
Existing chronic pain drugs are only partly effective, and only for some patients, and they are associated with significant side effects. Our mission is to develop safe and effective medicines for neuropathic pain treatment.
Our team has taken our lead candidate PN6047 successfully through pre-clinical studies and it is now engaged in first-in-man clinical studies. This is a great achievement for a small Biopharma company. Today, I am totally convinced that we can deliver safe and effective medicines for the treatment of chronic, neuropathic pain”.
Bengt von Mentzer, founder and chief scientific advisor
